erythromycin ointment
akorn, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 5 mg in 1 g - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. for prophylaxis of ophthalmia neonatorum due to n. gonorrhoeae or c. trachomatis . the effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing n.gonorrhoeae is not established. for infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin g should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. topical prophylaxis alone is inadequate for these infants. this drug is contraindicated in patients with a history of hypersensitivity to erythromycin.
erythromycin- erythromycin solution
teligent pharma, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin topical solution is indicated for the topical treatment of acne vulgaris. erythromycin topical solution is contraindicated in those individuals who have shown hypersensitivity to any of its components.
novo-rythro ethylsuccinate pws powder for solution
novopharm limited - erythromycin (erythromycin ethylsuccinate) - powder for solution - 200mg - erythromycin (erythromycin ethylsuccinate) 200mg - erythromycins
novo-rythro ethylsuccinate pws powder for solution
novopharm limited - erythromycin (erythromycin ethylsuccinate) - powder for solution - 100mg - erythromycin (erythromycin ethylsuccinate) 100mg - erythromycins
novo-rythro ethylsuccinate pwr 400mg/5ml powder
novopharm limited - erythromycin (erythromycin ethylsuccinate) - powder - 400mg - erythromycin (erythromycin ethylsuccinate) 400mg - erythromycins
e-mycin 400 erythromycin 400mg/5ml powder for oral liquid
alphapharm pty ltd - erythromycin ethyl succinate, quantity: 468 mg (equivalent: erythromycin, qty 400 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity
e-mycin 200 erythromycin 200mg/5ml powder for oral liquid
alphapharm pty ltd - erythromycin ethyl succinate, quantity: 234 mg (equivalent: erythromycin, qty 200 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity
erythromycin solution
nucare pharmaceuticals,inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin topical solution usp, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical solution usp, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.
erythromycin solution
nucare pharmaceuticals,inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin topical solution, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical solution, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free
pinewood healthcare - erythromycin ethyl succinate - oral suspension - 25mg/1ml